心率变异性联合临床与实验室指标预测脓毒症患者病情恶化
研究纳入急诊科1247例符合1992年共识会议脓毒症标准且能签署知情同意的21岁及以上患者,记录就诊1小时内的临床、实验室及心率变异性(HRV)数据,随访72小时内的病情恶化。832例数据完整者中68例(8%)达到至少一个终点。联合实验室值与HRV指标的模型预测性能最佳,AUROC为0.80(95%CI 0.65-0.92),优于单独临床指标(AUROC=0.69,95%CI 0.54-0.83)、单独实验室指标(AUROC=0.77,95%CI 0.63-0.90)和单独HRV指标(AUROC=0.76,95%CI 0.61-0.90)。HRV+LAB模型识别出高风险组(占全部患者14%)恶化风险为4.3倍(95%CI 3.2-5.4),恶化发生率35%;低风险组(占61%)风险为0.2倍(95%CI 0.1-0.4),恶化发生率2%。作者认为该模型可能有助于急诊医生评估脓毒症患者的恶化风险,值得验证和进一步评估。
要点
- 联合HRV与实验室指标的模型预测脓毒症恶化的AUROC为0.80(95%CI 0.65-0.92),优于单独临床、实验室或HRV指标。
- HRV+LAB模型识别的高风险组(占14%)恶化风险为4.3倍(95%CI 3.2-5.4),恶化发生率35%。
- 低风险组(占61%)恶化风险为0.2倍(95%CI 0.1-0.4),恶化发生率2%。
- 研究纳入符合1992年共识会议脓毒症标准的急诊成人患者,于就诊1小时内采集数据,随访72小时。
- 作者认为该模型可能帮助急诊医生评估恶化风险,但尚需验证和进一步评估。
适用人群与场景
- 急诊科21岁及以上患者,符合1992年共识会议脓毒症标准,且能直接或通过代理人签署知情同意。
诊断标准与关键阈值
- 脓毒症诊断采用1992年共识会议标准。
- 恶化终点为72小时内达到至少一个终点(原文未具体列出终点定义)。
研究设计与关键结果
- 研究类型为预测模型推导与性能评估,纳入1247例急诊脓毒症患者,832例数据完整,其中68例(8%)达到至少一个终点。
- 联合实验室值与HRV指标的模型AUROC为0.80(95%CI 0.65-0.92),优于单独临床指标(AUROC=0.69,95%CI 0.54-0.83)、单独实验室指标(AUROC=0.77,95%CI 0.63-0.90)和单独HRV指标(AUROC=0.76,95%CI 0.61-0.90)。
- HRV+LAB模型识别的高风险组占全部患者的14%,恶化风险为4.3倍(95%CI 3.2-5.4),恶化发生率为35%。
- HRV+LAB模型识别的低风险组占全部患者的61%,恶化风险为0.2倍(95%CI 0.1-0.4),恶化发生率为2%。
证据类型、等级与局限
- 证据类型:预测模型推导与性能评估研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为联合HRV与实验室指标的模型可能帮助急诊医生评估脓毒症患者的恶化风险,但需验证和进一步评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Risk stratification of patients presenting to the emergency department (ED) with sepsis can be challenging. We derived and evaluated performance of a predictive model containing clinical, laboratory, and heart rate variability (HRV) measures to quantify risk of deterioration in this population.
METHODS: ED patients aged 21 and older satisfying the 1992 consensus conference criteria for sepsis and able to consent (directly or through a surrogate) were enrolled (n = 1,247). Patients had clinical, laboratory, and HRV data recorded within 1 h of ED presentation, and were followed to identify deterioration within 72 h.
RESULTS: Eight hundred thirty-two patients had complete data, of whom 68 (8%) reached at least one endpoint. Optimal predictive performance was derived from a combination of laboratory values and HRV metrics with an area under the receiver-operating curve (AUROC) of 0.80 (95% CI, 0.65-0.92). This combination of variables was superior to clinical (AUROC = 0.69, 95% CI, 0.54-0.83), laboratory (AUROC = 0.77, 95% CI, 0.63-0.90), and HRV measures (AUROC = 0.76, 95% CI, 0.61-0.90) alone. The HRV+LAB model identified a high-risk cohort of patients (14% of all patients) with a 4.3-fold (95% CI, 3.2-5.4) increased risk of deterioration (incidence of deterioration: 35%), as well as a low-risk group (61% of all patients) with 0.2-fold (95% CI 0.1-0.4) risk of deterioration (incidence of deterioration: 2%).
CONCLUSIONS: A model that combines HRV and laboratory values may help ED physicians evaluate risk of deterioration in patients with sepsis and merits validation and further evaluation.
参考来源
- Barnaby DP, Fernando SM, Herry CL, et al. Heart Rate Variability, Clinical and Laboratory Measures to Predict Future Deterioration in Patients Presenting With Sepsis. Shock. 2019. PMID: 29847498. doi:10.1097/SHK.0000000000001192
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。